Guideline for Evaluating Persistent Gastrointestinal Symptoms in Patients with Celiac Disease

Diagnostic Monitoring

In patients with celiac disease, follow‑up serologic testing for anti‑tissue transglutaminase IgA should be performed at 6 months, at 12 months after diagnosis, and then annually to monitor disease control. 1
Measurement of TG2‑IgA antibodies is the recommended laboratory assessment to detect ongoing gluten exposure in celiac disease patients. 1

A negative TG2‑IgA result does not guarantee mucosal healing, because antibody assays have limited sensitivity for low‑level dietary transgressions. Clinicians should therefore not rely solely on serology to confirm disease remission. 1
Persistent or relapsing gastrointestinal symptoms in celiac disease patients warrant endoscopic biopsy even when serology is negative, to directly assess intestinal mucosal status. 1

Esophagogastroduodenoscopy with duodenal biopsies should be performed in celiac disease patients who have ongoing symptoms without an obvious cause, irrespective of serologic findings. This procedure provides definitive evidence of mucosal healing or ongoing injury. 1
Biopsy results can reveal continued celiac‑related mucosal damage despite negative serology, underscoring the need for histologic confirmation before concluding disease control. 1

Before attributing gastrointestinal complaints to tirzepatide therapy, clinicians must verify that the patient’s celiac disease diagnosis is accurate, that the gluten‑free diet is being adhered to, and that serologic and, if needed, histologic evaluations confirm disease control. 1
If serology remains positive for TG2‑IgA, this indicates ongoing intestinal injury and continued gluten exposure, prompting dietary reassessment and possible repeat endoscopy. 1
When serology is negative but symptoms persist, the guideline advises proceeding to endoscopic biopsy rather than assuming disease remission. 1

Persistently positive anti‑tissue transglutaminase (anti‑TG2) antibodies generally indicate ongoing intestinal injury and ongoing gluten ingestion. 2
Follow‑up serologic testing is advised at 6 months and 12 months after diagnosis, and subsequently on an annual basis. 2
A negative serologic result does not assure mucosal healing because current antibody assays have limited sensitivity for detecting low‑level dietary transgressions. 2
Reducing or eliminating gluten exposure before diagnostic testing lowers the sensitivity of both serologic assays and duodenal biopsy for detecting celiac disease. 2

Even small amounts of inadvertent gluten can keep antibody titres elevated and impede complete intestinal recovery. 3

In patients with ongoing symptoms and persistent positive serology, clinicians should: